Encoded Therapeutics closed a $275 million Series F round to advance its Dravet syndrome genetic medicine program and scale internal manufacturing. The round was led by GV and included an undisclosed healthcare investor, adding substantial non-dilutive momentum to a precision medicine strategy. While details of the capital allocation weren’t fully spelled out, the company explicitly linked funding to both clinical progress and scaling production capacity. In genetic medicines, manufacturing scale-up can directly influence trial expansion, dosing logistics, and global supply planning. For the sector, the move highlights investor appetite for high-conviction rare disease programs with clear manufacturing pathways. It also reflects a broader pattern where later-stage private rounds support platform expansion as much as individual asset advancement. The Encoded financing may also increase competitive pressure in Dravet and adjacent channelopathies as firms seek to convert early clinical signals into durable development runways.